UBS Maintains Chemed at Buy, Raises Price Target to $675
UBS maintained its Buy rating on Chemed and raised its price target to $675 from $650.
Related stories
Cousins Properties Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 11:13 PM UTC
Australia’s S&P/ASX 200 rises 0.4% to 8,928.10
M impact | EQUITY | Oct 29, 2026, 11:12 PM UTC
Pinnacle Bank announces third-quarter 2026 earnings
Pinnacle Bank announced earnings for the third quarter of 2026.
M impact | EQUITY | Oct 29, 2026, 11:11 PM UTC
Coles Group Reports Quarterly Sales Revenue of A$11,209 Million
M impact | EQUITY | Oct 29, 2026, 11:10 PM UTC
Medallion Financial Reports Quarterly Results
Medallion Financial Corp reported results for the quarter ended September 30; the supplied text provides no figures.
M impact | EQUITY | Oct 29, 2026, 11:10 PM UTC
TMX Group announces availability of third-quarter 2026 results release
TMX Group announced that its third-quarter 2026 results release is available.
M impact | EQUITY | Oct 29, 2026, 11:10 PM UTC